NeoGenomics, Inc.
NEO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.01 | -0.03 | 0.48 |
| FCF Yield | 0.29% | 7.49% | -12.34% | -0.43% |
| EV / EBITDA | -44.58 | -16.08 | -79.28 | 178.01 |
| Quality | ||||
| ROIC | -2.17% | -3.66% | -1.84% | -1.13% |
| Gross Margin | 42.84% | 42.61% | 43.59% | 44.92% |
| Cash Conversion Ratio | -0.33 | -0.45 | 0.98 | -0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.25% | 7.70% | 8.27% | 9.02% |
| Free Cash Flow Growth | -95.93% | 146.96% | -1,557.98% | -15.84% |
| Safety | ||||
| Net Debt / EBITDA | -24.74 | -9.31 | -40.97 | 64.69 |
| Interest Coverage | 0.00 | -51.05 | -17.20 | -11.33 |
| Efficiency | ||||
| Inventory Turnover | 3.77 | 3.05 | 3.18 | 3.54 |
| Cash Conversion Cycle | 20.42 | 81.78 | 93.86 | 83.65 |